Ernexa Therapeutics (ERNA) Gross Margin (2016 - 2024)
Historic Gross Margin for Ernexa Therapeutics (ERNA) over the last 13 years, with Q4 2024 value amounting to 5.26%.
- Ernexa Therapeutics' Gross Margin rose 1052600.0% to 5.26% in Q4 2024 from the same period last year, while for Dec 2024 it was 81.0%, marking a year-over-year decrease of 266900.0%. This contributed to the annual value of 81.0% for FY2024, which is 2490000.0% up from last year.
- Ernexa Therapeutics' Gross Margin amounted to 5.26% in Q4 2024, which was up 1052600.0% from 112.32% recorded in Q3 2024.
- Over the past 5 years, Ernexa Therapeutics' Gross Margin peaked at 112.32% during Q3 2024, and registered a low of 135.29% during Q3 2023.
- Over the past 3 years, Ernexa Therapeutics' median Gross Margin value was 29.79% (recorded in 2024), while the average stood at 27.04%.
- As far as peak fluctuations go, Ernexa Therapeutics' Gross Margin plummeted by -89700bps in 2020, and later skyrocketed by 2476100bps in 2024.
- Ernexa Therapeutics' Gross Margin (Quarter) stood at 60.32% in 2020, then tumbled by -266bps to 100.0% in 2023, then skyrocketed by 105bps to 5.26% in 2024.
- Its Gross Margin stands at 5.26% for Q4 2024, versus 112.32% for Q3 2024 and 102.13% for Q2 2024.